Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Asthma

Treatments: Drug: Placebo; Drug: Zavegepant

Study type: Interventional

Funder types: Industry

Identifiers

NCT04987944

BHV3500-204

C5301005 (Other Identifier)

Details and patient eligibility

About

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

Enrollment: 45 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with Asthma

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Single Blind

---

45 participants in 2 patient groups, including a placebo group

BHV3500

Experimental group

Description:

Zavegepant 150 mg BID

Treatment:

Drug: Zavegepant

Placebo

Placebo Comparator group

Description:

Matching placebo 150 mg BID

Treatment:

Drug: Placebo